Research & Development (R&D) department
Approximately ten people are working within the Research & Development (R&D) department of Winclove, each within his or her own field of expertise. Our R&D team has great expertise and knowledge on every aspect related to probiotics and the management of the intestinal microbiota.
Do you want to know more about our research department? Read here our R&D curriculum vitae.
At the moment the R&D department is working on the following clinical trials:
IBS Study with Ecologic® COMFORT
At the Maastricht University Medical Centre (MUMC) in the Netherlands, a clinical trial is running with IBS patients that are hypersensitive. Ecologic® COMFORT was specifically designed for this application. The study has a double-blind, placebo-controlled design and patients receive Ecologic® COMFORT or placebo during 4 weeks. At the beginning and end of the intervention period the hypersensitivity of the patients is measured with the Barostat technique. At the moment the latest patients are being included into the study. The MUMC expects to be able to present the results within a few months.
Constipation study with Ecologic® RELIEF in pregnant women
At the Academic Medical Centre (AMC) in Amsterdam, the Netherlands, a clinical trial is running with pregnant women that have defecation problems, during the third trimester of their pregnancy. Pregnant women that have serious constipation problems receive Ecologic® RELIEF or a placebo during a period of 4 weeks. Clinical parameters measured include defecation frequency and stool consistency. A publication of this study is expected within a few months.
Patients with decreased barrier function receiving Ecologic® 825
In Germany a clinical trial has started in September 2011. In this trial, patients with a reduced barrier function will receive Ecologic® 825 for a period of 8 weeks. Several clinical parameters will be analyzed. A follow-up study is planned to start after this trial, with the new formulation Ecologic® BARRIER.
Migraine patients receiving Ecologic® BARRIER
In Wageningen in the group of human nutrition a pilot study is started with 29 migraine patients. During 3 months these patients will receive Ecologic® BARRIER and they will record the frequency and intensity of their migraine attacks in dairies.
Follow-up Ecologic® PANDA trial
The children at high risk for atopic diseases, that were included in the double-blind placebo-controlled trial with Ecologic® PANDA (showing prevention of eczema at 3 months and a continuation of these results after 1 and 2 years), are now 5-6 years old. The Wilhelmina Children’s Hospital of the University Medical Centre in Utrecht, the Netherlands, is now examining the occurrence of asthma in this group of children, to determine whether the preventive use of Ecologic® PANDA (during the first year of life) still has an effect at the age of 5-6. Results of this investigation are expected in 2012.
Do you want more information about our R&D department or do you have specific questions with regard to product development? Please contact us.
